Johnson & Johnson(JNJ)
USD --+0.00%
Reward56Moderate
Risk15Low
75%Data
Strong 22% profit margin · 2.0% dividend yield
JNJ
+0.0 · +0.00%
USD · NYSE
Johnson & Johnson | Healthcare
Market Cap:618.61Bn
ⓘ
Reward Rating
56
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
15
Low
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on JNJ to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for JNJ, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Johnson & Johnson?

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.

What is Johnson & Johnson?

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 618.61B, and a P/E ratio of 29.8x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (56)
Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
Market Cap618.61B
P/E Ratio29.7775
Dividend Yield2.01%
Beta0.235
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
330,142 shares
$7.4M
0
6-9months
0
0
9-12months
0
0

Openbook research

Latest analysis

JNJ
Browse all research